Divi's Laboratories

Divi's Laboratories Limited is an Indian producer of active pharmaceutical ingredients (APIs) and intermediates headquartered in Hyderabad, Telangana, India.[5][6][7][8] The company manufactures and custom synthesizes generic APIs, intermediates and nutraceutical ingredients.[9][10] Divi's Laboratories is India's second most valuable pharmaceutical company by market capitalization.[11]

Divi's Laboratories Limited
FormerlyDivi's Research Centre
TypePublic
ISININE361B01024
IndustryPharmaceuticals
Founded12 October 1990 (1990-10-12)
Headquarters1-72/23(P)/DIVIS/303, Divi Towers Cyber Hills, Gachibowli 500032,
Hyderabad, Telangana
,
India
Key people
  • Murali Krishna Prasad Divi (MD)
  • Satchandra Kiran Divi (CEO)
Products
Revenue ₹5,584.05 crore (US$780 million) [1] (2020)
₹1,819.46 crore (US$260 million) [1] (2020)
₹1,376.54 crore (US$190 million) [1] (2020)
Total assets ₹8,535.70 crore (US$1.2 billion) [1] (2020)
Total equity ₹7,309.92 crore (US$1.0 billion) [1] (2020)
Owner
  • Divi Satchandra Kiran (20.34%)
  • Nilima Motaparti (20.34%)
  • Divi Swarna Latha (5.27%)
  • Divis Biotech Private Limited (3.01%)
  • Murali Krishna Prasad Divi (2.85%)
Number of employees
13,884 (2020)
Subsidiaries
  • Divis Laboratories (USA) Inc
  • Divi’s Laboratories Europe AG
Websitedivislabs.com
Footnotes / references
[1][2][3][4]

History

Divi's Laboratories was established in 1990 as Divi's Research Centre. The company initially started developing commercial processes for the manufacturing of APIs and intermediates. Divi's Research Centre changed its name to Divi's Laboratories Limited in 1994 to signal its intent to enter the API and intermediates manufacturing industry.[12] Following this, the company established its first Manufacturing facility in 1995 at Choutuppal, Telangana.[13] In 2002, the company's second manufacturing facility commenced operations at Chippada near Visakhapatnam.[13]

The company went public with its IPO on 17 February 2003.[14][15] In 2010, the company established a research centre in Hyderabad.[13]

Facilities

The company has six manufacturing facilities and three R&D centres across India:[13]

Manufacturing

References
  1. Laboratories, Divi's. "Annual Report" (PDF). divislabs.com. Archived (PDF) from the original on 18 October 2020.
  2. Inc., Bloomberg. "Divi's Laboratories Ltd Company profile". Bloomberg L.P. Archived from the original on 18 October 2020. Retrieved 15 September 2020.
  3. "Latest Shareholding Pattern - Divi's Laboratories Ltd". trendlyne.com. Archived from the original on 18 October 2020. Retrieved 15 September 2020.
  4. Laboratories, Divi's. "Subsidiary Financials" (PDF). divislabs.com. Archived (PDF) from the original on 18 October 2020.
  5. "Company Profile-DIVIS LAB". Dynamic Levels. Archived from the original on 18 October 2020. Retrieved 15 September 2020.
  6. "Company Profile for Divi's Laboratories Ltd". Reuters. Archived from the original on 18 October 2017. Retrieved 15 September 2020.
  7. Inc., Bloomberg. "Divi's Laboratories Ltd Company profile". Bloomberg L.P. Archived from the original on 18 October 2020. Retrieved 15 September 2020.
  8. "DIVI'S LABORATORIES LIMITED - Company, directors and contact details | Zauba Corp". www.zaubacorp.com. Archived from the original on 18 October 2020. Retrieved 15 September 2020.
  9. "Top API Manufacturing Company In Hyderabad, India & World | DivisLabs". Divis Laboratories World’s largest API manufacturing facility. Archived from the original on 12 August 2020. Retrieved 15 September 2020.
  10. Bradstreet, Dun. "Divi's Laboratories company profile". dnb.com.
  11. Sonavane, Ravindra N. (10 August 2020). "Divi's Labs beats drugmakers to become India's 2nd most valuable pharma company". mint. Archived from the original on 15 August 2020. Retrieved 15 September 2020.
  12. "Divis Laboratories > Company History > Pharmaceuticals > Company History of Divis Laboratories - BSE: 532488, NSE: DIVISLAB". moneycontrol.com. Archived from the original on 6 June 2020. Retrieved 17 September 2020.
  13. Laboratories, Divi's. "Annual Report" (PDF). Archived (PDF) from the original on 18 October 2020.
  14. "Divis Labs Fixes Rs 130 Per Share As Floor Price For IPO". The Financial Express. 11 February 2003. Archived from the original on 17 March 2018. Retrieved 18 September 2020.
  15. "Divis Laboratories > Company History > Pharmaceuticals > Company History of Divis Laboratories - BSE: 532488, NSE: DIVISLAB". moneycontrol.com. Archived from the original on 6 June 2020. Retrieved 19 September 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.